EXELA Pharma Sciences, LLC Announces the Launch of ELCYS™ (cysteine hydrochloride injection), USP, and the Only FDA Approved Cysteine Hydrochloride Injection marketed in the United States
May 31, 2019 | Comments Off on EXELA Pharma Sciences, LLC Announces the Launch of ELCYS™ (cysteine hydrochloride injection), USP, and the Only FDA Approved Cysteine Hydrochloride Injection marketed in the United States

Lenoir, NC May 31, 2019 – Exela Pharma Sciences is pleased to announce the approval and immediate launch of ELCYS™ (cysteine hydrochloride injection), USP, the only FDA Approved cysteine hydrochloride injection on the market in the United States. ELCYS™ was approved under priority review as a New Drug Application (NDA). It is not an Abbreviated New Drug Application (ANDA) product. The NDA is the result of significant research and development aimed at lowering the Aluminum content in the drug product.   ELCYS™ is labeled to contain no more than 120 parts per billion (mcg/L) of Aluminum. ELCYS™ is indicated for use
Read More